Halozyme Therapeutics (HALO) has suffered a legal setback in Germany after a Higher Regional Court overturned a preliminary injunction that had previously blocked Merck (MRK) from distributing Keytruda’s subcutaneous (SC) formulation in the country. The original injunction, granted in December 2025, had prevented Merck from offering the drug in Germany. Halozyme expressed disappointment with the court’s decision and plans to file a patent infringement lawsuit against Merck, seeking permanent relief.
The stock of Halozyme dropped 2.9% following the announcement, despite a strong year-to-date performance of 38.3%, significantly outpacing the industry’s 5.7% increase. The legal dispute revolves around Halozyme’s MDASE patent portfolio, which covers technology for rapid subcutaneous drug administration using modified human hyaluronidases.
In a separate but related case, a Dutch patent court ruled in Halozyme’s favor in October 2026, prohibiting Merck from manufacturing, offering, selling, or using Keytruda SC in eight European countries. This ruling does not affect the German proceedings, as the two cases are independent. Halozyme emphasized that its MDASE patents are distinct from its ENHANZE drug delivery technology patents, meaning the outcome of the MDASE dispute will not impact its existing licensing agreements with companies like J&J (JNJ) and argenx (ARGX).
Halozyme’s collaboration agreements with major pharmaceutical companies generate significant revenue through royalties, milestone payments, and annual license fees. The company currently holds a Zacks Rank #3 (Hold).